# US 2012/0252901 A1 · Agomelatine and pharmaceutical compositions thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252901 A1
- Document ID: US20120252901A1
- Status: Published application
- Kind: A1
- Application number: 13/504,769
- Filed: 2010-12-13
- Published: 2012-10-04
- Earliest claimed: 2009-12-23
- Assignees: Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd
- Inventors: Jianqiang Zhu; Qingson Tian; Jian Zhao
- Web page: https://patentgrep.com/patent/US20120252901A1

## CPC

- C07C 231/24: Separation; Purification
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61P 25/24: Antidepressants
- C07C 233/18: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Agomelatine crystal, which is a drug for treating depression, and pharmaceutical compositions thereof are provided. The X-ray powder diffraction spectra of such agomelatine crystal, which is irradiated by Cu-Kα and showed by 2θ(degree), has characteristic diffraction peaks at 12.84, 13.84, 16.14, 18.56, 19.12, 20.86, 21.20, 23.84; its IR absorption pattern has characteristic absorption peaks at about 3234, 3060, 2940, 1638, 1511, 1436, 1249, 1215, 1184, 1032, 908, 828, 755, 588 cm-1, and its DSC endothermic transition temperature is 97.6° C. The use of the agomelatine crystal as an active ingredient in preparing a medicament for the treatment of depression is also provided.

## Claims

### Claim 1

A crystal of agomelatine, which is characterized by X-ray powder diffraction pattern in the 2θ using Cu-Kα radiation as shown in FIG. 1: the IR absorption pattern thereof has characteristic absorption peaks at 3234, 3060, 2940, 1638, 1511, 1436, 1249, 1215, 1184, 1032, 908, 828, 755, 588 cm−1, and DSC shows an endothermic transition at 97.6° C.

### Claim 2 (depends on 1)

The agomelatine crystal according to claim 1, wherein X-ray powder diffraction pattern in the 2θ using Cu-Kα radiation has characteristic diffraction peaks at 12.84, 13.84, 16.14, 18.56, 19.12, 20.86, 21.20, 23.84.

### Claim 3 (depends on 1)

A method for the preparation of agomelatine crystal according to claim 1, which is characterized by: crude agomelatine is dissolved in DMF, filtered and the filtrate is poured into distilled water with rapid stirring and maintained for 15-45 min, subsequently the solution is filtered and dried.

### Claim 4 (depends on 3)

The preparation method according to claim 3, wherein the weight ratio of said filtrate to distilled water is 1:20-50.

### Claim 5 (depends on 1)

A pharmaceutical composition, which contains a therapeutically effective amount of agomelatine crystal as defined in claim 1, and one or more pharmaceutically acceptable carriers.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein said composition is an oral formulation.

### Claim 7 (depends on 1)

A method for the treatment of depression, wherein the method comprises administrating the agomelatine crystal as defined in claim 1.
